熱門資訊> 正文

Moolec Science报告第三季度业绩

2024-05-30 18:13

Moolec Science press release (NASDAQ:MLEC): Q3 Normalized revenues and other income (Ex-IAS 29) up ~$1.3M Y/Y given consolidation of soy-protein ingredient business.
R&D, Admin and other expenses of $2.3M increased 68% Y/Y mainly due to non-cash items.
Operational cash utilization the quarter of ~$2.6M includes ~$1.4M allocated to lower accounts payable.

More on Moolec Science

Moolec achieves USDA approval for plant-grown animal proteins, shares jump
Seeking Alpha’s Quant Rating on Moolec Science
Historical earnings data for Moolec Science
Financial information for Moolec Science

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。